Innovative Industrial Properties (IIPR) Q2 2026 earnings summary

Executive summary

• Diversified REIT with $2.4B invested across cannabis and life sciences, spanning 108 properties in 19 U.S. states, with 95.8% leased as of June 30, 2026 and a weighted-average lease term of 11.9 years.

• Completed $270 million investment in IQHQ, including $120 million Series G preferred equity funded in Q2 2026, enhancing sector diversification.

• Achieved meaningful leasing momentum, including new leases at five properties totaling 389,000 sq ft and a new 58,000 sq ft lease in Ohio.

• Faced tenant defaults and lease terminations, notably with PharmaCann, 4Front Ventures, Gold Flora, TILT Holdings, Cannabist, and Parallel, impacting rental revenues and occupancy.

• Strengthened balance sheet with $402.5 million exchangeable notes offering, full repayment of $291 million senior notes, and significant liquidity of $299.7 million.

Financial highlights

• Q2 2026 total revenues were $63.3 million, up 0.7% year-over-year from $62.9 million, with AFFO at $53 million ($1.83 per share) and net income attributable to common stockholders of $40.7 million ($1.36 per share).

• AFFO per share grew at a 7% CAGR from 2020 to Q2 2026 (annualized), reaching $7.32.

• Dividends per share grew at a 9% CAGR over the same period, totaling over $1.2B paid since inception, with a declared $1.90 per share dividend for Q2 2026.

• Total return since inception in 2016 is 486%.

• Interest and other income rose to $10.8 million from $1.6 million year-over-year, driven by IQHQ investment and seller-financed note.

Outlook and guidance

• Management remains optimistic about growth opportunities in both life sciences and cannabis, focusing on selective, accretive capital deployment.

• Arrangements with new tenants for 4Front assets expected to be effective by year-end 2026 or early 2027, subject to contingencies.

• Ongoing efforts to transfer licenses for PharmaCann properties to new tenants.

• Cannabis industry projected to grow at 8% CAGR from 2025 to 2030; life sciences market opportunity expanding, driven by AI-enabled discovery and limited new supply.

• Federal rescheduling of medical cannabis to Schedule III in April 2026 may improve cash flow for operators.